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Abstract
Background: The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions
for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide vaccine
demands and manufacturing restrictions urge for more detailed dose sparing studies.
The establishment of complementary biomarkers in addition to PRNT and Viremia could support a secure
decision-making regarding the use of 17DD YF vaccine subdoses. The present work aimed at comparing the serum
chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine.
Methods: Neutralizing antibody titers, viremia, cytokines and chemokines were tested on blood samples obtained
from eligible primary vaccinees.
Results and discussion: The results demonstrated that a fifty-fold lower dose of 17DD-YF vaccine (587 IU) is able to
trigger similar immunogenicity, as evidenced by significant titers of anti-YF PRNT. However, only subdoses as low as
3,013 IU elicit viremia kinetics with an early peak at five days after primary vaccination equivalent to the current dose
(27,476 IU), while other subdoses show a distinct, lower in magnitude and later peak at day 6 post-vaccination. Although
the subdose of 587 IU is able to trigger equivalent kinetics of IL-8/CXCL-8 and MCP-1/CCL-2, only the subdose of
3,013 IU is able to trigger similar kinetics of MIG/CXCL-9, pro-inflammatory (TNF, IFN-γ and IL-2) and modulatory
cytokines (IL-5 and IL-10).
Conclusions: The analysis of serum biomarkers IFN-γ and IL-10, in association to PRNT and viremia, support the
recommendation of use of a ten-fold lower subdose (3,013 IU) of 17DD-YF vaccine.
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Background
The yellow fever (YF) virus is a mosquito-borne flavivirus
that causes hemorrhagic disease with jaundice in people
inhabiting tropical areas [1-3]. The incidence of YF dropped
significantly after the development of live attenuated vac-
cines in the 1930s [3]. The YF vaccines (17D and 17DD)
are one of the most successful prophylactic interventions
for controlling disease expansion ever designed and utilized
in larger scale [4].
Recent evidences for expansion of viral circulation in
tropical areas estimate that over 900 million people are at
risk of infection [5]. It is now effective that the YF vaccine
is been currently used to protect travelers and is incor-
porated in childhood vaccination programs in many
countries, with millions of doses distributed annually
around the globe. Up to present, there are 6 producers
of yellow fever vaccines, but only 4 are prequalified by
the World Health Organization and supply vaccines to
international agencies: Bio-Manguinhos (Brazil), Sanofi-
Pasteur (France), Institute Pasteur in Dakar (Senegal) and
Chumakov Institute - Institute of Poliomyelitis and viral
encephalitides (Russia Federation) [6]. In 2008, the
sudden increase on the demand for YF vaccine forced
Bio-Manguinhos, the Brazilian supplier of 17DD vaccine,
to interrupt any vaccine exporting to other countries [7].
This sudden rise in vaccine demand was due to the large
epidemic of yellow fever in tropical South America, caused
by the increase of Aedes aegypti infestation levels in
many urban cities, in addition to the frequent move-
ment of susceptible individuals from yellow fever-free
to endemic areas [7].
Thus, the spreading of risk areas and the restricted
group of YF vaccine manufacturers creates a shortage on
YF vaccine supply worldwide, which urges for new
strategies of vaccination protocols including validation
of new seed lots, need and timing of booster doses to
maintain long lasting protection as well as dose sparing
studies [8]. In regards to dose, the minimal number of
viral particles has been established by WHO as at least
5,000PFU or approximately 3,000 IU. However, the ma-
ximum dose has not been established [5,9]. Previous studies
have reported that the number of virions in the 17DD-YF
vaccine produced by Bio-Manguinhos/FIOCRUZ is on
average approximately seven times higher (2.3 to 12.0
times) than the minimal dose established by WHO [5,9].
The fine-tuning of the vaccine dose in current use to
lower number of viral particles, above the minimum re-
quired by WHO, could increase the vaccine availability
and supply the worldwide increasing needs. However, it is
important to guarantee that lower doses are able to induce
similar protection [9]. It has been proposed by Lopes et al.
[10] that doses higher than 200 PFU (approximately
100 IU) were able to induce 100% of seroconversion.
However, recent evidence has shown that doses as low
as 47 times (1,122PFU or 587 IU) the reference are re-
quired to induce equivalent seroconversion rates [5,9]. It is
clear that a better understanding of the virological/im-
munological features upon YF subdoses vaccination is rele-
vant to further support changes in the minimal dose
recommended by the YF-vaccination guidelines. Therefore,
in the present study, individuals who had primary vacci-
nation with subdoses of the 17DD-YF vaccine were tested
for virological/immunological serum biomarkers, such
as the viral load, chemokines and cytokines as well as
neutralizing antibody titers. The kinectics of such bio-
markers, taken in association, highly advice for alterna-
tive and equivalent vaccination protocols with subdoses
of the 17DD-YF vaccine.
Methods
Design of the study
The present study was performed by the Collaborative
Group for Studies of Yellow Fever Vaccine aiming to
investigate virological and immunological features
induced by subdoses of the 17DD-YF Vaccine after
approval of the Ethical Committee for studies with
human subjects (CPqRR/FIOCRUZ #22/2010). The study
population consisted of 900 healthy, adult (age average -
19.4 years), army, male conscripts from Rio de Janeiro
enrolled in a screening phase. All participants informed
not being vaccinated for Yellow Fever previously and
agreed with and signed a written consent form. Partici-
pants were distributed randomly into six study groups
(150 subject/group) each of which were given different the
currently used dose of 17DD-YF vaccine (27,476 IU -
52,480PFU) and five alternative formulation with decreas-
ing number of viral particles (10,447 IU - 19,953PFU;
3,013 IU - 5,754PFU; 587 IU - 1,122PFU; 158 IU -
302PFU and 31 IU - 59PFU), as shown in Figure 1.
Excluding criteria were: 1) missing blood collection at
Baseline (n = 50), 2) insufficient serum sample volume
(n = 147), 3) Seropositivity (PRNT ≥ 2.70 log10 mIU/mL)
at Baseline (n = 75) or 4) timeline interval of blood collec-
tion >34 days (n = 37). The eligible population (n = 590)
was selected for pairing with baseline sample according
to the number of blood samples available (two blood
samples, n = 295→ 295 pairs and three blood samples,
n = 295→ 590 pairs), resulting in a total of 885 paired
samples. Paired samples were grouped according to dose
given and referred as 27,476 IU (n = 157), 10,447 IU
(n = 144), 3,013 IU (n = 150), 587 IU (n = 140), 158 IU
(n = 145) and 31 IU (n = 149). The experimental design
consisted of eight timepoints: before (Baseline) and
days after primary vaccination (D3, D4, D5, D6, D7,
D15 and D30). Each timepoint was comprised in aver-
age of 21 paired samples for each dose. The Plaque
Reduction Neutralization Test (PRNT) was performed
at baseline and D30. Viremia was assayed at D3, D4,
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D5, D6 and D7. Chemokines and cytokines were evalu-
ated at Baseline, D3, D4, D5, D6, D7, D15 and D30.
The volunteers who showed negative PRNT results at
D30 (n = 35) were revaccinated with the current vac-
cine. PRNT follow-up of those volunteers with positive
PRNT results after primary vaccination (PV-PRNT+,
n = 555) was performed in a final blood sample col-
lected at endpoint (D365).
Neutralizing antibody test – PRNT
The antibody titer against Yellow Fever virus was
defined by the Plaque Reduction Neutralization Test
Figure 1 Flowchart illustrating the study population and experimental design. The study was organized in four phases: Screening, Sampling,
Grouping and Design. “Screening” of volunteers was performed taking into account: i) missing blood collection at baseline (n = 50); ii) insufficient
sample volume (n = 147); iii) seropositivity at baseline (n = 75) and iv) timeline interval of blood collection >34 days and <365 days after primary
vaccination (n = 37). The eligible population comprises 590 primovaccinees. “Sampling” consisted of either two (n = 295) or three (n = 295) blood
collections. The serum samples were paired to their respective sample collected at baseline, resulting in a total of 885 baseline-paired samples.
“Grouping” was performed according to the dose of 17DD YF vaccine administered (27,476 IU; 10,447 IU; 3,013 IU; 587 IU; 158 IU and 31 IU). Paired
samples were further subcategorized according and the timepoint (days) in which the sample was collected (Baseline; D3; D4; D5; D5; D7(7–12); D15
(13–25) and D30(26–34). A final blood collection of these volunteers was taken at 365 days after primary vaccination (n = 555) to monitor anti-YF
antibody status. “Design” included: i) PRNT assays performed at baseline, D30 and D365; ii) Viremia quantified at D3, D4, D5, D6 and D7 and iii) Kinetics
of serum chemokines and cytokines evaluated from baseline to D30.
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(PRNT) performed at Virological Technology Laboratory
of Bio-Manguinhos (LATEV, FIOCRUZ). This test was
conducted as previously described [9,11]. Briefly, sera
samples from the participants were separated, inactivated
and prepared as 2-fold dilution starting at 1:5, in volumes
of 50 μl of samples in flat-bottom 96-well tissue culture
plates. Twenty-five plaque-forming units (PFU) of yel-
low fever virus (strain 17D 213/77, lot UEXVFB01, Dec
1011) in 50 μl were added to all wells. A positive serum
sample with anti-Yellow Fever virus antibody, properly
calibrated by a WHO International Reference Prepar-
ation agency, was included in each set of the test. Using
linear regression, the log10 dilution of the test and
standard serum that reduced the plaque numbers in
50% relative to the virus control was determined. The
mean antibody titer at the 50% end-point of the stand-
ard serum is then calculated and added to the log10
end-point for each sample in order to obtain the values
in log10 mIU/ml. Results are presented in log10 mIU/
mL. The 2.7 log10 mIU/mL cut-off point was applied to
segregate seropositive from seronegative samples as de-
scribed previously [9].
Viremia
The RNA of Human serum samples from vaccinated pa-
tients with Yellow Fever vaccine was extracted using
QIAamp® Viral RNA Mini kit (QIAGEN®) according to the
manufacturer’s recommendations. Reverse transcription
reaction was performed with random primers (F: 5′
GCACGGATGTAACAGACTGAAGA3′ and R: 5′CCAG
GCCGAACCTGTCAT 3′) in 20 μL of the extracted RNA
added to 20 μL of High-Capacity cDNA Reverse Transcrip-
tion mix (Applied Biosystems®). The qRT-PCR assays were
performed in the ABIPrism 7500 (Applied Biosystems®)
using the probe Fam-CGACTGTGTGGTCCGGCCCA
TC-Tamra, directed to the NS5 region of the yellow
fever virus [12,13]. For constructing the standard curves,
the 83 bp fragments from the NS5 viral region obtained
by PCR [12] was cloned into a TOPO TA Cloning vector,
according to the manufacturer’s instructions (Invitrogen®).
Serial dilutions from 107 to 102 plasmid copies per reac-
tion were used to generate the calibration curves for the
qRT-PCR assays. The lowest detected concentration was
established in 25 copies/reaction.
Chemokine and cytokine quantitation by flow
cytometry - CBA
To assess the levels of chemokines – IL-8/CXCL-8, MCP-
1/CCL-2, MIG/CXCL-9, IP-10/CXCL-10 and cytokines –
TNF, INF-γ, IL-2, IL-4, IL-5 and IL-10 – in serum samples
from 17DD-YF vaccinees, Cytometric Bead Array kits (BD
Biosciences, California, USA) were used according to man-
ufacturer’s protocol and adapted as described previously
[14]. Analysis of raw data was performed using the FlowJo
cytometry analysis software (FlowJo, Stanford, USA) and
the mean fluorescence intensity (MFI) of each bead
cluster was evaluated to calculate the each cytokine
concentration in the sera of patients. Cytokines concen-
trations were extrapolated according to the standard
curve created by serial dilutions of the positive control.
The final data for the kinetics timeline design were
expressed as fold changes based on the baseline concen-
tration for all chemokines and cytokines tested.
Data analysis
The overall kinetics profile of viremia, chemokine and
cytokines elicited by 17DD-YF vaccine subdoses were
evaluated in comparison to the current dose (27,476 IU)
as standard. Equivalence between current dose and
subdoses was considered when the median fold change
at a given timepoint did not differ as compared to the
current dose (Man-Whitney test). The peaks of fold
changes along the timeline were also taken into account
as a relevant feature for equivalence assessment and
highlighted by *. The analyses of PRNT titers were per-
formed in a categorical fashion using the cut-off point
of 2.7 log10IU/mL as a threshold to segregate positive
from negative results. Gray-colored rectangles were
used to highlight equivalence in the kinetics profiles.
The Prism GraphPad Software version 5.0 (San Diego,
CA, USA) and Microsoft Office Excel 2010 were used
for kinetics timeline graphic arts and data mining.
Results
A fifty-fold lower dose of 17DD-YF vaccine is able to trigger
similar immunogenicity as evidenced by significant titers of
anti-yellow fever virus neutralizing antibodies
The current dose of Yellow Fever vaccine distributed
by Bio-Manguinhos is 27,476 IU, which is approxi-
mately seven times higher than the dose recommended
by WHO. Therefore, in order to investigate the im-
munogenicity of lower doses of the 17DD Yellow Fever
vaccine, a dose-sparing study was designed and per-
formed including six doses of 17DD-YF vaccine as
shown in Figure 1.
Figure 2A shows the results on the Plaque Reduction
Neutralization Test (PRNT) in sera samples of volun-
teers vaccinated by several doses of 17DD Yellow Fever
vaccine. The threshold of 2.70 log10 mIU/mL was used
as a cut-off to segregate seropositive from seronegative
samples. The results show that seropositivity was high
among vaccinees of all doses with percentages above
97% of seroconversion down to dose 587 IU of YF
vaccine. At doses 158 IU and 31 IU, the percentage of
seroconversion was 89% and 57%, respectively.
Additional analysis of PRNT at D365 indicated that
only the lower dose (31 IU) was associated with signi-
ficant seroreversion. In fact, only 89% of primary
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vaccinees that received the 31 IU subdose persisted
with positive PRNT results one year after primary
vaccination (Additional file 1: Figure S1).
A ten-fold lower dose of 17DD-YF vaccine elicits equivalent
viremia kinetics with an early peak at five days after
primary vaccination
Figure 2B shows the kinetics timeline of Viremia follow-
ing 17DD-YF primary vaccination with the dose cur-
rently used and subdoses. It is possible to observe a
significant viremia peak at D5 after primary vaccination
with the doses 27,476 IU, 10,447 IU and 3,013 IU. The
kinectics of viremia at the lower doses is distinct, with a
late and lower-magnitude peak at D6 post-vaccination.
A Fifty-fold lower dose of 17DD YF vaccine is able to
trigger equivalent kinetics of IL-8/CXCL-8 and MCP-1/
CCL-2 as observed for PRNT seropositivity.
Figure 3 shows the results of IL-8/CXCL-8 and MCP-
1/CCL-2 kinetics in sera samples from Yellow Fever
vaccinees. The chemokine results are displayed as Base-
line fold changes for each timepoint. Data analysis
demonstrates that doses as low as 587 IU are able to in-
duce similar kinetics for IL-8/CXCL-8 and MCP-1/




Figure 2 Immunogenicity and Viremia kinetics following 17DD-YF primary vaccination with different doses (27,476 IU-current;
10,447 IU; 3,013 IU; 587 IU; 158 IU and 31 IU). (A) Anti-YF neutralizing antibody titers (• = current dose and fades for subdoses) were measured
by PRNT assay carried out 26–34 days (D30) after primary vaccination, as described in Methods. PRNT antibody titers are expressed in log10 mIU/mL
and 2.7 log10 mIU/mL as the cut-off point to segregate seropositive from seronegative samples. Significant seropositivy rates (>95%) are highlighted
by gray rectangle. (B) Viremia ( = current dose and fades for subdoses) was quantified by Real-time PCR at D3, D4, D5, D6 and D7 after primary
vaccination as described in Methods. Viremia results are expressed in copies/mL. Kinetics profiles equivalent to current dose (27,476 IU) are highlighted
by gray rectangle. The peaks of fold changes along the timeline were also taken into account as a relevant feature for equivalence assessment and
highlighted by *.
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The MIG/CXCL-9 kinetics induced by a ten-fold downscaled
dose resembles the current dose as observed for the
viremia kinetics
Figure 3 also shows the results of MIG/CCL-9 and IP-10/
CXCL-10 kinetics in sera samples from Yellow Fever vacci-
nees. For the MIG/CCL-9, similar increasing kinetics with
peak at D6 was observed upon vaccination with doses
as low as 3,013 IU specifically one day after the viremia
peak (Figures 2 and 3, respectively). The chemokine
IP-10/CXCL-10 displayed the highest baseline fold
change magnitude (up to 6 times) with peak of produc-
tion at D7, except at the lowest dose of vaccine (31 IU),
which showed an inverted kinetics profile.
The kinetics of pro-inflammatory cytokines (TNF,
IFN-γ and IL-2) progresses similarly down to a ten-fold
lower dose of 17DD-YF vaccine.
Figure 4 displays the results of the baseline fold
changes in the serum pro-inflammatory cytokines TNF,
Figure 3 Kinetics of serum chemokines following 17DD-YF primary vaccination with different doses (27,476 IU-current; 10,447 IU;
3,013 IU; 587 IU; 158 IU and 31 IU). Serum levels of IL-8/CXCL-8 ( ), MCP-1/CCL-2 ( ), MIG/CXCL-9 ( ) and IP-10/CXCL-10 ( ) were
measured by cytometric beads array (CBA) as described in Methods. The colors assigned for the current dose fade away for subdoses. Results
are expressed as baseline fold change of each timepoint (Serum level/D0). Kinetics profiles equivalent to current dose (27,476 IU) are
highlighted by gray rectangle. The peaks of fold changes along the timeline were also taken into account as a relevant feature for equivalence
assessment and highlighted by *.
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IFN-γ and IL-2. The kinetics of these cytokines dem-
onstrates similar peak of TNF and IFN-γ at D5 after
vaccination with the doses 27, 476IU, 10,447IU and
3,013IU in agreement with the peak of viremia. IL-2
production display peak approximately one day after
TNF and IFN-γ (D6 or D7) for the these three higher
doses. Conversely, the IL-2 kinetics induced by the
three lowest doses (587IU, 158IU and 31IU) is charac-
terized by a shift of IL-2 peak towards D30.
Peaks and troughs of IL-10 serum levels upon vaccination
with 17DD YF vaccine – a distinguished modulatory cyto-
kine kinectics
Figure 5 demonstrates the results of baseline fold
changes for the regulatory cytokines (IL-4, IL-5 and
IL-10). The IL-4 secretion pattern was very similar
throughout the subdoses, with late peak at Day 30 re-
gardless of the vaccine dose given. For IL-5 and IL-10,
similar kinetics profiles were observed to doses as low
Figure 4 Kinetics of pro-inflammatory cytokines following 17DD-YF primary vaccination with different doses (27,476 IU-current; 10,447 IU;
3,013 IU; 587 IU; 158 IU and 31 IU). Serum levels of the pro-inflammatory cytokines TNF ( ), IFN-γ ( ) and IL-2 ( ) were measured by cytomet-
ric beads array (CBA) as described in Methods. The colors assigned for the current dose fade away for subdoses. Results are expressed as baseline fold
change of each timepoint (Serum level/D0). Kinetics profiles equivalent to current dose (27,476 IU) are highlighted by gray rectangle. The peaks of fold
changes along the timeline were also taken into account as a relevant feature for equivalence assessment and highlighted by *.
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as 3,013 IU. However, IL-10 production presented a
distinguished modulatory cytokine kinectics with early
peak at day 3 with subsequent trough after day 4 or day
5 that upsurges at day 6, whereas IL-5 peaks at day 30
as observed for IL-4. Lower doses of the vaccine do not
present the specific IL-10 peak and through kinetics,
but rather present inverted pattern with increased IL-10
production in either earlier or later timepoints.
IFN-γ and IL-10 are relevant complementary bio-
markers that in addition to PRNT and viremia support a
safe use of ten-fold lower subdose of 17DD YF vaccine
The overall analysis of serum chemokine and cytokines
in addition to PRNT and viremia allowed the identifica-
tion that six out of ten biomarkers (MIG/CXCL-9, TNF,
IFN-γ, IL-2, IL-5 and IL-10) display equivalent kinetics
timeline with viremia and PRNT (Figure 6A). On the
Figure 5 Kinetics of regulatory cytokines following 17DD-YF primary vaccination with different doses (27,476 IU-current; 10,447 IU;
3,013 IU; 587 IU; 158 IU and 31 IU). Serum levels of the regulatory cytokines IL-4 ( ), IL-5 ( ) and IL-10 ( ) were measured by cytometric
beads array (CBA) as described in Methods. The colors assigned for the current dose fade away for subdoses. Results are expressed as baseline
fold change of each timepoint (Serum level/D0). Kinetics profiles equivalent to current dose (27,476 IU) are highlighted by gray rectangle. The
peaks of fold changes along the timeline were also taken into account as a relevant feature for equivalence assessment and highlighted by *.
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other hand, biomarkers (IL-8/CXCL-8 and MCP-1/CCL-
2) were demonstrated as similar in kinetics with the
PRNT positivity. Two biomarkers (IP-10/CXCL-10 and
IL-4) did not display any similarity with PRNT and
viremia, the current conventional correlates of protec-
tion (Figure 6A).
It is important to highlight that IFN-γ and IL-10 are
relevant complementary biomarkers associated with
the viremia kinetics. Together, these biomarkers in
addition to PRNT and viremia could support the safe
use of ten-fold lower subdose (3,013 IU) of 17DD YF
vaccine (Figure 6B). The 3,013 IU subdose induced
A
B
Figure 6 Snapshot of immunological and virological biomarkers following 17DD-YF primary vaccination with different doses
(27,476 IU-current; 10,447 IU; 3,013 IU; 587 IU; 158 IU and 31 IU). (A) Selection of biomarkers with equivalent kinetics timeline with viremia
and PRNT [Viremia ( ); PRNT ( ); IL-8/CXCL-8 ( ); MCP-1/CCL-2 ( ); MIG/CXCL-9 ( ); IP-10/CXCL-10 ( ); TNF ( ), IFN-γ ( ) and IL-2
( );IL-4 ( ), IL-5 ( ) and IL-10 ( )]. (B) Overlay graphs highlighting that IFN-γ and IL-10 are relevant complementary biomarkers associated
with the viremia kinetics. Results are expressed as the global maximum values of each timepoint to baseline (viremia, , range 0 to 1.6E + 04
copies/mL; INF-γ, , range 0 to 4 baseline fold; IL-10, , range 0 to 2 baseline fold).
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IL-10 trough simultaneously to viremia and IFN-γ peaks
at D5, similar to the dose currently used (Figure 6B).
Discussion
In the present study, individuals vaccinated with sub-
doses of 17DD vaccine were tested for several molecules
such as cytokines, chemokines as well as the viral load
and the neutralizing antibody titers in a time and dose-
dependent fashion. The kinectics of these molecules
were thoroughly investigated taking into consideration
several vaccine doses and immune biomarkers of effect-
ive vaccination were proposed.
The results demonstrated that a fifty-fold lower dose
of 17DD-YF vaccine (587 IU) is able to trigger similar
immunogenicity as evidenced by significant titers of
anti-YF PRNT. However, it is important to consider
whether the load of antigen exposure during primary
vaccination would affect immunogenicity. Only subdoses
as low as 3,013 IU elicit viremia kinetics with an early
peak at five days after primary vaccination equivalent to
the current dose (27,476 IU), while other subdoses show
a distinct, lower in magnitude and later peak at day 6
post-vaccination. It is well described that an optimal
antigen exposure is necessary for the generation of
protective response. In the context of live-attenuated
virus, lower doses of vaccine should be able to elicit
ideal immunogenicity since the virus replicates within
the organism and amplifies its antigenic exposure. This
fact indicates that viremia results should be taken
together with PRNT titers on the decision making for
dose sparing [9,10,15].
In addition to that, although subdoses as low as
587 IU is able to trigger equivalent kinetics of IL-8/
CXCL-8 and MCP-1/CCL-2, only subdoses downscaled
to 3,013 IU are able to trigger similar kinetics of MIG/
CXCL-9, pro-inflammatory (TNF, IFN-γ and IL-2) and
modulatory cytokines (IL-5 and IL-10).
It is important to note that our results indicate that
even subdoses of 17DD yellow fever vaccine have the
proper amount of YF vaccine virus to compensate for
the possible loss during transportation of the vaccine or
when the cold chain is not secured. In addition, the vac-
cine formulation is comprised of sorbitol and gelatin,
which are used as vaccine stabilizers, and the vaccine
preparation is lyophilized, allowing for more stability of
the vaccine formulation.
Previous studies have demonstrated that the balance
of cytokines is crucial to generate a pro-inflammatory
response upon vaccination [16-22]. In this regard, TNF-
α is an important molecule in this scenario. TNF-α pro-
duced by neutrophils and monocytes upon antigenic
stimuli seem to play a role in inducing an initial pro-
inflammatory response in either primo-vaccination or
upon re-vaccination [22]. The levels of this cytokine also
correlate with the PRNT titers, which indicates that the
production of TNF-α may be important to generate an
immunological environment for production of neutraliz-
ing antibodies [22].
Conversely, the lack of seroconversion after YF-17DD
primary vaccination promotes a regulatory status upon
antigen recall, with lower synthesis of TNF-α by neutro-
phils and monocytes. In addition, the absent production
of neutralizing antibodies correlates with enhanced syn-
thesis of modulatory cytokines such as IL-10 produced
by CD8+ T cells compared with all other groups [22].
These results are in agreement with the present find-
ings that indicate a peaks and troughs in IL-10 levels
that are opposite to viremia peaks and peak levels of
TNF-α and IFN-γ. The trough of IL-10 levels at day 5
may be associated with retreated modulatory response
during peak viremia, which allows for the development
and maturation of antigen presenting cells (APCs) as
well as higher expression of MHC in the surface of these
APCs [19]. The assembly of neutralizing antibodies is
dependent upon antigenic presentation, mediated by
MHC-II presentation by APCs, which endorses the data
associating lower IL-10 synthesis, and higher TNF-α
and IFN-γ production with PRNT titers and Viral load
(Figure 6). The late IL-2 production may be associated
with proliferation and clonal expansion of memory CD4+
and CD8+ T cells [21].
The kinetics observed in this study was very similar to
the one found in previous study demonstrating early and
strong cytokine production on 5–7 days after vaccin-
ation [18]. The overall cytokine secretion kinetics of
17DD YF vaccinees showed a transient peak of pro-
inflammatory molecules and viral load along with trough
of IL-10 secretion at day 5, which draws back toward a
mixed/regulatory pattern at later times points in day 15
and day 30. A robust early response is important for
maintaining a protective response as indicated by neu-
tralizing antibodies.
Regarding the standardization of the serum bio-
markers, we believe that the measuring of viremia,
cytokines and chemokines could be easily standard-
ized for regular use. Our group has advanced in this
respect as previously described [14]. In addition, Chao
et al. [13] and Jonsson et al. [23] have already de-
scribed the correlation between the quantitation of
YFV by real-time PCR and TCID50 or plaque assay
lysis, which indicates that viral load could be imple-
mented as a test with high likelihood to plaque assay
lysis [13,23].
All in all, the results indicate that subdoses of 17DD
vaccines are able to elicit neutralizing antibodies, peak
viremia and strong pro-inflammatory response in a time-
line similar to the one observed with a higher dose in
current used.
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Conclusions
The analysis of serum biomarkers IFN-γ and IL-10, in
association to PRNT and viremia, support the recom-
mendation of use of a ten-fold lower subdose (3,013 IU)
of 17DD-YF vaccine.
Additional file
Additional file 1: Figure S1. Persistence of Anti-YF neutralizing antibody
titers one year after 17DD-YF primary vaccination with different doses
(27,476 IU-current; 10,447 IU; 3,013 IU; 587 IU; 158 IU and 31 IU). PRNT assay
was carried out 365 days (D365) after primary vaccination, as described in
Methods. PRNT antibody titers (• = current dose and fades for subdoses)
are expressed in log10 mIU/mL and 2.7 log10mIU/mL as the cut-off point to
segregate seropositive from seronegative samples. Significant persistence of
seropositivity (>95%) as compared to D30 is highlighted by gray rectangle.
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